IND
KQTD-126 (pan-TRK inhibitor)
IND submitted (US), not yet in effect per company
Since , the date of the source that reports this phase.
Summary
KQTD-126 is a pan-TRK inhibitor from XtalPi. The source describes it as small molecule (gut-restricted). It is being developed for chronic intestinal pain (IBS and IBD). Per the company, it was at IND submitted (US), not yet in effect as of Sep 29, 2026. The AI role named in the source is molecule design. The latest dated source is from Sep 29, 2026.
Built only from the sources listed on this page.
Facts
- Company
- XtalPi
- Indication
- Chronic intestinal pain (IBS and IBD)
- Therapeutic area
- Other
- Modality
- Small molecule (gut-restricted)
- AI role
- Molecule design
- Phase in the source
- IND submitted (US), not yet in effect, as of Sep 29, 2026
- Phase source
- X only
- Board column
- IND
- Trial record
- none (IND stage)
AI evidence
AI source: Company
“XtalPi leveraged its generative and predictive AI models integrated with its fleet of automated chemistry robots.”
Milestone timeline
-
Official X post: IND submitted (US), not yet in effect
Spot an error? Tell me and I'll fix it.